Biotest wins FDA approval for plasma protein therapy

17 Jun 2024
www.pharmaceutical-technology.com
Clinical ResultDrug ApprovalPhase 3ImmunotherapyAcquisition
Biotest wins FDA approval for plasma protein therapy
Preview
Source: Pharmaceutical Technology
The FDA approved Biotest’s plasma protein therapy as per a 17 June press release. Credit: Biotest.
Biotest, a subsidiary of GrifolsGrifols, announced that the US FDA granted approval for its plasma protein therapy Yimmugo earlier today (17 June).
Yimmugo is an intravenous immunoglobulin therapy developed as a substitution therapy for primary antibody deficiency syndromes. The Barcelona, Spain-headquartered company launched the therapy in Europe in late 2022, receiving European Medicines Agency (EMA) approval for production and marketing. Biotest is developing the therapy at a production facility in Dreieich, Germany. The therapy uses a polyvalent immunoglobulin G preparation from human blood plasma for producing intravenous administration (IVIg).
Antibody deficiency syndrome is caused by an immunoglobulin level significantly under the standard range or a failure of immunoglobulin function. The primary form of the condition is developed due to genetic defects that dysregulate B cell development and/or function.
Earlier this year, Biotest announced an 83.6% increase in first-quarter (Q1) sales driven by Yimmugo. The company reported revenues of €215.2m ($230.5m) in Q1 2024, with Yimmugo’s sales jumping from €7.5m to €11.1m.
In a 17 June press release, Peter Janssen, Biotest’s CEO, said: “With this approval, we aim to increase the availability of and access to immunoglobulin therapies worldwide, thereby improving patient care.”
See Also:Johnson & Johnson seeks FDA approval for Tremfya for Crohn’s disease
Biotest wins FDA approval for plasma protein therapy
Preview
Source: Pharmaceutical Technology
AstraZeneca’s Truqap and Faslodex combo receives approval in EU
Biotest wins FDA approval for plasma protein therapy
Preview
Source: Pharmaceutical Technology
Alongside Yimmugo, Biotest has been developing two other plasma proteins. One of these is a fibrinogen concentrate therapy, AdFIrst (BT524), for the treatment of acquired fibrinogen deficiency. In 2021, Biotest came under GrifolsGrifols via the acquisition of Tiancheng Pharmaceutical, which owned a majority of the shares in Biotest. Earlier this year, Grifols’ chief scientific innovations officer, Jörg Schüttrumpf, said the company has the capability to manufacture Adfirst in-house.
GrifolsGrifols released a positive readout from a Phase III AdFIrst study (2017-001163-20) in February 2024, demonstrating that the therapy was non-inferior to the standard of care. Biotest is also developing trimodulin (BT-588), a plasma protein treatment for severe community-acquired pneumonia. The pharma company is currently investigating the therapy in the Phase III ESsCAPE study (NCT05722938).
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.